Cardiff Oncology (CRDF) Stock Forecast & Price Target

Cardiff Oncology is poised for success with their promising results from the CRDF-004 trial and plans for a randomized Phase 3 trial later this year. With a high ORR and potential reduction in the risk of progression or death, there is high potential for onvansertib to become a preferred treatment for 1L RAS+ mCRC. The company also anticipates few barriers to uptake of onvansertib thanks to its clean safety profile and simple addition to standard-of-care therapy.

Cardiff Oncology is currently in its clinical stage and has a limited geographic reach of only the United States. With only one main drug in its pipeline, onvansertib, the company faces significant risk and uncertainty. The recent update on the Phase II trial for onvansertib showed positive results, but it is still too early to determine its long-term success. Additionally, with a projected market cap of $428 million and a net debt of $6 million, the company's current valuation may not be entirely justified.